Jade Biosciences, Inc. (JBIO)
| Market Cap | 1.04B +274.2% |
| Revenue (ttm) | n/a |
| Net Income | -95.10M |
| EPS | -2.11 |
| Shares Out | 49.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,126,067 |
| Open | 20.91 |
| Previous Close | 20.84 |
| Day's Range | 20.43 - 21.67 |
| 52-Week Range | 6.57 - 28.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 36.29 (+72.48%) |
| Earnings Date | May 7, 2026 |
About JBIO
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for JBIO stock is "Strong Buy." The 12-month stock price target is $36.29, which is an increase of 72.48% from the latest price.
News
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on devel...
Jade Biosciences announces first participant dosed in JADE201 Phase 1 trial
Jade Biosciences (JBIO) announced the first participant has been dosed in a first-in-human Phase 1 clinical trial of JADE201. JADE201 is an investigational, half-life extended, afucosylated monoclonal...
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on deve...
Jade Biosciences announces first participant dosed in Phase 2 Juniper trial
Jade Biosciences (JBIO) announced that the first participant has been dosed in Juniper, the Company’s Phase 2 trial evaluating JADE101 in participants with immunoglobulin A nephropathy. JADE101 is des...
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on devel...
Jade Biosciences price target raised to $34 from $24 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Jade Biosciences (JBIO) to $34 from $24 and keeps an Outperform rating on the shares. Preliminary Phase 1 JADE101 data…
Jade Biosciences price target raised to $32 from $23 at Guggenheim
Guggenheim raised the firm’s price target on Jade Biosciences (JBIO) to $32 from $23 and keeps a Buy rating on the shares. Following the Q1 update, the firm is revising…
Jade Biosciences files $600M mixed securities shelf
17:17 EDT Jade Biosciences (JBIO) files $600M mixed securities shelf
Jade Biosciences files to sell 39.54M shares of common stock for holders
17:22 EDT Jade Biosciences (JBIO) files to sell 39.54M shares of common stock for holders
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
SAN FRANCISCO and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-c...
Jade Biosciences Registration statement: Registration filing
Jade Biosciences filed a registration statement on May 7, 2026, providing details about a securities offering with the SEC.
Jade Biosciences Registration statement: Registration filing
Jade Biosciences filed a registration statement on May 7, 2026, providing details about a securities offering with the SEC.
Jade Biosciences Quarterly report: Q1 2026
Jade Biosciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
Jade Biosciences Earnings release: Q1 2026
Jade Biosciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Jade Biosciences Slides: Company presentation
Jade Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Jade Biosciences Proxy statement: Proxy filing
Jade Biosciences filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Jade Biosciences Proxy statement: Proxy filing
Jade Biosciences filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Jade Biosciences price target raised to $45 from $35 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Jade Biosciences (JBIO) to $45 from $35 and keeps a Buy rating on the shares. The company is set to report data…
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on dev...
Jade Biosciences appoints Edward Conner as chief medical officer
Jade Biosciences (JBIO) announced the appointment of Edward Conner as chief medical officer, effective immediately. Conner joins Jade from Ardelyx (ARDX) where he served as CMO.
Jade Biosciences Appoints Edward R. Conner, M.D.
SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on dev...
Jade Biosciences Proxy statement: Proxy filing
Jade Biosciences filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Jade Biosciences price target raised to $35 from $25 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Jade Biosciences (JBIO) to $35 from $25 and keeps a Buy rating on the shares following the Q4 report. The firm increased…
Jade Biosciences participates in a conference call with William Blair
Analyst Matt Phipps holds a conference call with management on March 19 at 2:15 pm hosted by William Blair. Webcast Link
Jade Biosciences price target raised to $39 from $28 at BTIG
BTIG raised the firm’s price target on Jade Biosciences (JBIO) to $39 from $28 and keeps a Buy rating on the shares. The firm is positive on the company’s potential…